Product Sales, Pipeline & Biosimilar Timelines Key Themes For Roche 2Q
Executive Summary
Investors during Roche’s second-quarter update on Thursday will look for updates on coming biosimilar competition, promising pipeline assets, and the delayed Spark Therapeutics acquisition.